Amazon affiliate link
Alcohol pads
MED PRIDE, 70% isopropyl, 200 count per listing. An alcohol pad does not establish sterility of a research product.
View on Amazon ↗Immune research
Thymosin alpha-1
research guide
Thymosin alpha-1 is a thymic peptide studied for immunomodulatory effects across human trials in sepsis and COVID-19. A sepsis meta-analysis of 11 randomized controlled trials reported a significant overall mortality reduction that did not hold in high-quality or multicenter subgroup analyses. A separate COVID-19 meta-analysis pooling 9 studies (not all randomized) found no significant overall mortality benefit and did not support hospitalized use, though some patient subgroups showed benefit.
Evidence depends on population and formulation. Literature summary, not clinical peer review.
Looking for the product? Reign listings and business disclosure ↓
Jorge Abreu is not a doctor. This is an educational research summary, not a prescription or a personal dosing plan. Study results do not establish that a supplier product is safe or effective for people. Consult a licensed clinician about medical decisions.
01 · Start with identity
What is Thymosin alpha-1?
Thymosin alpha-1 is a defined 28 amino acid peptide with a substantial history of clinical trial research, distinct from research-chemical peptides that have only preclinical data. This page does not address regulatory approval status in any jurisdiction, since that was not verified from an official regulatory source in this research.
Also searched as: Tα1, thymalfasin
02 · Read the evidence
What the studies reported
01
Sepsis 28-day mortality meta-analysis
A meta-analysis of 11 randomized controlled trials (967 patients on thymosin alpha-1, 960 controls) reported a significant reduction in 28-day mortality overall (odds ratio 0.73, 95% CI 0.59 to 0.90, p = 0.003), but subgroup analyses restricted to high-quality trials (odds ratio 0.82, 95% CI 0.65 to 1.03, p = 0.09) and multicenter trials (odds ratio 0.86, 95% CI 0.68 to 1.08, p = 0.20) did not show a significant mortality benefit, and the authors noted the current evidence base is inadequately powered [1].
02
COVID-19 meta-analysis found no overall mortality benefit
A systematic review and meta-analysis pooling 9 studies (5352 patients: 1152 on thymosin alpha-1, 4200 controls), not all of which were randomized controlled trials, found no statistically significant effect on mortality overall (risk ratio 1.03, 95% CI 0.60 to 1.75, p = 0.92, I-squared 90 percent), and the authors concluded their results do not support use of thymosin alpha-1 in hospitalized adult COVID-19 patients; a mortality benefit appeared only in specific subgroups such as patients over age 60 and severe/critical cases [2].
03 · Numbers in context
What does dosing evidence actually support?
The cited sepsis meta-analysis pooled 11 randomized controlled trials (967 vs 960 patients) assessing 28-day mortality, and the COVID-19 meta-analysis pooled 9 studies (5352 patients total, not all randomized) assessing mortality; both used doses set by the original individual trial protocols in hospitalized patients, which are not reproduced here. These are pooled clinical trial results in specific hospitalized populations, reported as historical study findings only, not a general recommendation.
A study dose is not a personal dose. Population, route, formulation and supervision are part of the result. Online community schedules are not treated here as established clinical protocols.
04 · Safety and limits
What not to overlook
- The COVID-19 meta-analysis found no statistically significant overall mortality benefit and its authors stated results do not support use in hospitalized adult COVID-19 patients
- The sepsis meta-analysis's overall mortality benefit did not hold in high-quality or multicenter trial subgroups, and authors flagged the evidence base as underpowered
- The COVID-19 meta-analysis pooled 9 studies that were not all randomized controlled trials, which limits certainty
- Supplier research-chemical vials have not been shown to be equivalent to the clinical-grade product used in cited trials
05 · Product distinctions
Names are not interchangeable
Reign Peptide lists Thymosin Alpha-1 as a lyophilized powder (10mg/vial, greater than or equal to 99% purity by third-party HPLC per the listing), described by the supplier as for in-vitro research use only. This differs from the pharmaceutical-grade thymalfasin product used in the clinical trials summarized above, and no direct comparison between the two was identified in the sources reviewed.
06 · Handling and storage
Follow validated product instructions
A single water volume, refrigerator temperature or expiry window cannot be assumed for every compound and formulation. Use the exact manufacturer documentation and a validated laboratory procedure. If stability, solvent compatibility or microbiological quality is not documented, those properties remain unverified.
Refrigeration, clear appearance and bacteriostatic water do not make an unverified research product suitable for injection. This guide does not provide a mixing or administration procedure.
The existing concentration calculator checks arithmetic only. It cannot choose a safe dose or establish compatibility, sterility or shelf life.
Reign Peptide · Business disclosure
Research product listings
Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.
Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.
Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.
Supplies and accessories
Compare the actual specifications
Jorge's supply directory includes syringes, alcohol pads, storage cases, travel refrigeration and electrolytes, with separate links for the two travel refrigeration options. Accessory availability is not a recommendation to administer a research compound.
Affiliate disclosure: As an Amazon Associate I earn from qualifying purchases.
Amazon affiliate link
Peptide fridge case
Listing: 63 slots for 3mL bottles, bag only. An organizer is not active refrigeration or a validated storage system.
View on Amazon ↗Amazon affiliate link
Peptide travel case
Medineed travel case with temperature display and two ice packs per listing. Check dimensions and transport requirements.
View on Amazon ↗Questions still worth asking
What remains unresolved?
- Do the immune benefits observed in sepsis and COVID-19 trials extend to other infectious or immune conditions?
- How does a supplier research-chemical formulation compare pharmacokinetically to the pharmaceutical-grade product used in cited trials?
Check the source
References and evidence scope
- Human trial meta-analysis · 2025Efficacy of thymosin alpha1 for sepsis: a systematic review and meta-analysis of randomized controlled trials ↗
- Human trial meta-analysis · 2023Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes ↗
These are the sources reviewed for this page, not an exhaustive systematic review. Related compound research is identified as such. Product links are not scientific references.
Keep reading